Pauling.AI的动态

We've known of several therapies to extend healthy lifespan in animals for quite some time, including rapamycin, senolytics and others. But an important question is, why haven't these therapies made it from the lab to the clinic and to people? One reason is that they have never been proved in a clinical trial to actually extend lifespan in humans. Because nobody has ever paid to run such a trial. Unfortunately the economic reality of drug development is that taking a drug to market costs tens, if not hundreds of millions of dollars. So, the only drugs that are developed are the ones that can recover these costs. Which means drugs that are under patent protection. I believe the most promising path to get to therapies for longevity is new molecules, which can be patented, for diseases other than aging. But with reasonable evidence or data that shows impact in aging. Possibly following similar mechanisms to current therapies, but sold at much higher prices. I don't think over the next few years we will see fancy new partial reprogramming drugs, or gene therapies. But hopefully we will have rapalogs, senolytics and small molecule immunomodulators. And that may give us a few more years to continue working on the exciting stuff.